Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab – the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.

The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.

GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.

The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.